

IGF1R Enhances Calcium Oxalate Monohydrate-Induced Epithelial-Mesenchymal Transition by Reprogramming Metabolism via the JAK2/STAT3 Pathway

Jiashan Pan^{1,2,3*}, Yi Zhang^{1,2,3*}, Rui Yao^{1,2,3*}, Mo Yang^{1,2,3}, Xike Mao^{1,2,3}, Zhenyu Song^{1,2,3}, Yuexian Xu^{1,2,3}, Yang Chen^{1,2,3}, Bingbing Hou^{1,2,3}, Xiaoying Liu^{4#}, Wei Wang^{1,2,3#}, Zongyao Hao^{1,2,3#}

¹*Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China*

²*Institute of Urology, Anhui Medical University, Hefei, China*

³*Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei, China*

⁴*School of Life Sciences, Anhui Medical University, Hefei 230032, China; Henan International Joint Laboratory of Non-Coding RNA and Metabolism in Cancer, Henan Provincial Key Laboratory of Long Non-Coding RNA and Cancer Metabolism, Translational Research Institute of Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Henan 450053, China.*

*These authors contributed equally to this work.

#Corresponding Author: Zongyao Hao (ORCID <https://orcid.org/0009-0002-1586-5093>)

Department of Urology, The First Affiliated Hospital of Anhui Medical University and Institute of Urology and Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Jixi Road 218th, Shushan District, Hefei, Anhui, 230022, People's

Republic of China

Email: haozongyao@ahmu.edu.cn

Running title: *IGF1R Promotes EMT in COM-Induced Injury via JAK2/STAT3*

Figure number: 8

Supplemental figure number: 3

Supplemental table number: 5

Figure S1 The trend of IGF2R changes in HK2 cells induced by calcium oxalate monohydrate injury. (A) There is no significant difference in IGF2R between the COM group and the NC group at the mRNA level. (B) There is no significant difference in IGF2R between the COM group and the NC group at the protein level. COM: calcium oxalate monohydrate.




Figure S2 The results of quality control for transcriptomics and non-targeted metabolomics.

(A) PCA results of transcriptomics between the si-COM group and the si-IGF1R+COM group.

(B) PCA results of non-targeted metabolomics between the si-COM group and the

si-IGF1R+COM group. COM: calcium oxalate monohydrate.





Figure S3 The mRNA trends of glycolysis pathway-related proteases in calcium oxalate crystal-induced cell injury. HK2: Hexokinase, ENO1: Enolase 1, non-neuron, GPI: Phosphoglucose Isomerase, ALDOA: Aldolase, fructose-bisphosphate A, and PGK1:Phosphoglycerate Kinase-1



Supplementary Table S1 Primers of qRT-PCR used in this study

| Sequence of oligos used for quantitative real-time PCR of human genes | | |
|---|--------------------------------|--------------------------------|
| | Forward primer | Reverse primer |
| β-ACTIN | CCT GGC ACC CAG CAC AAT | GGG CCG GAC TCG TCA TAC |
| IGF1R | CAG AGG AGC TGG AGA TGG AG | TCT CAG CCT TGT GTC CTG AG |
| CDH1 | CGA GAG CTA CAC GTT CAC GG | GGG TGT CGA GGG AAA AAT AGG |
| CDH2 | AGC CAA CCT TAA CTG AGG AGT | GCG AAG TTG ATT GGA GGG ATG |
| VIMENTIN | AGT CCA CTG AGT ACC GGA GAC | CAT TTC ACG CAT CTG GCG TTC |
| SNAIL | TCG GAA GCC TAA CTA CAG CGA | AGA TGA GCA TTG GCA GCG AG |
| IL-1 β | ATG ATG GCT TAT TAC AGT GGC AA | GTC GGA GAT TCG TAG CTG GA |
| IL-6 | ACT CAC CTC TTC AGA ACG AAT TG | CCA TCT TTG GAA GGT TCA GGT TG |
| IL-10 | GAC TTT AAG GGT TAC CTG GGT TG | TCA CAT GCG CCT TGA TGT CTG |
| TNF- α | GAG GCC AAG CCC TGG TAT G | CGG GCC GAT TGA TCT CAG C |
| IGF2R | CAC CAA GTA GGC ACC ACT AAG | CAC CAA GTA GGC ACC ACT AAG |
| MCP-1 | CAG CCA GAT GCA ATC AAT GCC | TGG AAT CCT GAA CCC ACT TCT |
| CLCX1 | CTG CTC CTG CTC CTG GTA G | AGT GTG GCT ATG ACT TCG GT |
| CL3CX1 | GCC ACA GGC GAA AGC AGT A | GGA GGC ACT CGG AAA AGC TC |
| HK2 | GAG CCA CCA CTC ACC CTA CT | CCA GGC ATT CGG CAA TGT G |
| GPI | CAA GGA CCG CTT CAA CCA CTT | CCA GGA TGG GTG TGT TTG ACC |
| ALDOA | ATG CCC TAC CAA TAT CCA GCA | GCT CCC AGT GGA CTC ATC TG |
| ENO1 | AAA GCT GGT GCC GTT GAG AA | GGT TGT GGT AAA CCT CTG CTC |
| PGK1 | TGG ACG TTA AAG GGA AGC GG | GCT CAT AAG GAC TAC CGA CTT GG |
| STAT3 | CAG CAG CTT GAC ACA CGG TA | AAA CAC CAA AGT GGC ATG TGA |
| JAK2 | CTT TGC CCT GTA TGA CGA GAA C | ACC TCA TCC GGT AGT GGA GC |
| SLC2A1 | ACA GCG TTG ATG CCA GAC AG | GGC CAA GAG TGT GCT AAA GAA |
| PFKP | ACC TCC AGA ACG AAG GTC CTC | CGC CTA CCT CAA CGT GGT G |
| PFKM | AAG CAT CAT CGA AAC GCT CTC | GGT GCC CGT GTC TTC TTT GT |
| PFKL | CCT CTC ACA CAT GAA GTT CTC C | GTA CCT GGC GCT GGT ATC TG |
| PFKFB3 | TTG GCG TCC CCA CAA AAG T | AGT TGT AGG AGC TGT ACT GCT T |
| PKM | TGG GTG GTG AAT CAA TGT CCA | ATG TCG AAG CCC CAT AGT GAA |
| LDHB | TGG TAT GGC GTG TGC TAT CAG | TTG GCG GTC ACA GAA TAA TCT TT |
| GAPDH | AAA AGC GGG GAG AAA GTA GG | AAG AAG ATG CGG CTG ACT GT |
| LDHA | ATG GCA ACT CTA AAG GAT CAG C | CCA ACC CCA ACA ACT GTA ATC T |
| LDHA site 1 | AGC CAA CTT CAG CTC TCT G | AGG TTC TGA AAT GGG GCT C |
| LDHA site 2 | AGA GCC CCA TTT CAG AAC CT | GTG CAG TGA CTC ATG CCT GT |
| LDHA site 3 | GGC TCC TTC CTG AGG CTA TC | TCT GGG CCT GTA TTC TTG CT |

Supplementary Table S2 Primers of qRT-PCR used in this study

| Sequence of oligos used for quantitative real-time RT-PCR of mouse genes | | |
|--|--------------------------------|-------------------------------|
| | Forward primer | Reverse primer |
| β-Actin | GGC TGT ATT CCC CTC CAT CG | CCA GTT GGT AAC AAT GCC ATG T |
| IGF1R | G TG GGG GCT CGT GTT TCT C | GAT CAC CGT GCA GTT TTC CA |
| CDH1 | CAG TTC CGA GGT CTA CAC CTT | TGA ATC GGG AGT CTT CCG AAA A |
| CDH2 | AGG CTT CTG GTG AAA TTG CAT | GTC CAC CTT GAA ATC TGC TGG |
| Vimentin | CGT CCA CAC GCA CCT ACA G | GGG GGA TGA GGA ATA GAG GCT |
| Snail | CAC ACG CTG CCT TGT GTC T | GGT CAG CAA AAG CAC GGT T |
| IL-1β | GCA ACT GTT CCT GAA CTC AAC T | ATC TTT TGG GGT CCG TCA ACT |
| IL-6 | TAG TCC TTC CTA CCC CAA TTT CC | TTG GTC CTT AGC CAC TCC TTC |
| MCP-1 | AAG CTT CGC CCC ACA TGC CTC | TCT CGA GCT CAC GCG CAG G |
| IL-10 | GCT CTT ACT GAC TGG CAT GAG | CGC AGC TCT AGG AGC ATG TG |
| TNF-α | CCCTCACACTCAGATCATCTTCT | GCT ACG ACG TGG GCT ACA G |

Supplementary Table S3 Details of antibodies

| Antibodies | Company | Cat # | Dilution |
|--------------------------------|---------------------------|------------|----------|
| IGF1R | GenTex | GTX637795 | 1:2000 |
| IGF2R | Origene | TA351279 | 1:1000 |
| E-cadherin | Affinity | AF0131 | 1:1000 |
| N-cadherin | Origene | TA503933 | 1:1000 |
| Vimentin | Origene | TA801297S | 1:1000 |
| Snail | Origene | TA500366 | 1:1000 |
| STAT3 | Cell Signaling Technology | 9139 | 1:2000 |
| Phospho-Stat3 | Cell Signaling Technology | 9145 | 1:2000 |
| JAK2 | ABclonal | A7694 | 1:1000 |
| Phospho-JAK2 | ABclonal | AP0531 | 1:1000 |
| LDHA | Origene | TA500531 | 1:800 |
| KIM-1 | Abmart | MA8164S | 1:1000 |
| beta Actin | Affinity | AF7018 | 1:2000 |
| Goat Anti-Rabbit IgG H&L (HRP) | Zenbio | 511203 | 1:10000 |
| Goat Anti-mouse IgG H&L (HRP) | Zenbio | 511103 | 1:10000 |
| Goat Anti-Rabbit IgG H&L (HRP) | Proteintech | 30000-0-AP | 1:5000 |

Supplementary Table S4 siRAN and shRNA used in this study

| | Sense (5'-3') |
|-----------|---|
| si-NC | UUCUCCGAACGUGUCACGUTT |
| si-IGFR-1 | GC GGUGUCCAUAACUACAUU |
| si-IGFR-2 | TCATCAGCTTCACCGTTA |
| si-STAT3 | GCTGACCAACAATCCCAAGAA |
| si-LDHA | GCGTAACGTGAACATATTAA |
| sh-IGF1R | CCAACGAGCAAGTTCTCGTTtagtgaagccacagatgtaAACGAA GAACTTGCTCGT TGG |

Supplementary Table S5 Other reagents

| Product Name | Company | Cat # | Usage |
|-----------------------------------|-----------------|---------------|---|
| Calcium Oxalate Monohydrate (COM) | Sigma | 5794-28-5 | Mix with complete culture medium, and add 200 ng of the reagent to each well of a 6-well plate |
| Glyoxylic acid(Gly) | Sigma | G10601 | Dilute with physiological saline and administer intraperitoneally to mice at a concentration of 100 mg/kg |
| Stattic | TargetMol | T6308 | Stattic was used in 5 µM to inhibit the activation of STAT3 after we confirmed it had no effect on cell viability of HK-2 cell |
| Colivelin | TargetMol | TP1856 | For <i>in vivo</i> experiments, use a concentration of 1 mg/kg with a dissolution solution of 5% DMSO, 40% PEG300, 5% Tween 80, and 50% physiological saline, and perform continuous injections for 6 days. In <i>in vivo</i> experiments, use a concentration of 10 µM with a duration of 12 hours |
| Picropodophyllotoxin (PPP) | MedChem Express | HY-15494 | For <i>in vivo</i> experiments, use a concentration of 20 mg/kg, administer intraperitoneally twice daily, and continue for 7 days |
| 2-deoxyglucose (2-DG) | MedChem Express | HY-13966 | Pre-treat by adding the reagent 3 hours before adding calcium oxalate crystals, then add it together with calcium oxalate crystals to HK2 cells and replace the medium after 24 hours |
| 2-NBDG | MedChem Express | HY-11621 5 | Remove the cell culture medium and add fresh medium containing 2-NBDG (10 µM). Incubate at 37°C for 60 minutes. |